



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Kevin P. BAKER, et al.

Application Serial No. 10/006,818

Filed: December 6, 2001

For: **SECRETED AND
TRANSMEMBRANE
POLYPEPTIDES AND NUCLEIC
ACIDS ENCODING THE SAME**

) Examiner: Hamud, Fozia M.

) Art Unit: 1647

) Confirmation No: 1321

) Attorney's Docket No. 39780-2830 P1C4

) Customer No. 35489

EXPRESS MAIL LABEL NO. EV 766 020 203 US

DATE MAILED: MARCH 9, 2007

PRELIMINARY AMENDMENT

MAIL STOP RCE

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

Dear Sir:

On January 3, 2005, the Examiner made a final rejection to pending Claims 28-32. A Notice of Appeal was filed on May 27, 2005, and an Appeal Brief was filed on July 26, 2005. A Notice of Non-Compliant Appeal Brief was mailed October 31, 2005, and a revised Appeal Brief was filed November 22, 2005. An Examiner's Answer was mailed on April 3, 2006. In response, Applicants submitted a Request to Reopen Prosecution and a Response under 37 C.F.R. §1.111 on June 2, 2006. This Request was denied in an Office Communication mailed December 4, 2006. Applicants file herewith a Request for Continued Examination and a Preliminary Amendment. Please consider the following arguments.

The present Preliminary Amendment is further accompanied by the submission of a Declaration under 37 C.F.R. §1.132 by Dr. Paul Polakis, with attached Exhibits A and B. Also filed herewith is an Information Disclosure Statement providing copies of additional articles and abstracts in support of Applicants' arguments. Applicants note that some of the references listed in the Information Disclosure Statement are provided in the form of full-text articles, while others are provided as abstracts. Applicants submit that the full-text articles are provided solely

because they are available to Applicants. Applicants do not intend to make any distinction among the references, or to indicate that some references in the IDS are more pertinent or material than others. Applicants respectfully request that the information listed in the Information Disclosure Statement be considered by the Examiner and be made of record in the above-identified application.

Remarks/Arguments begin on page 3 of this paper.